As of June 12, 2018 our Privacy Policy has been updated. For individuals in the European Union, CIL uses cookies on this website. Please review the new privacy statement to see how. By continuing to use this website you agree to us using cookies in accordance with our privacy statement. Click here for the new privacy statement..OK

Corporate Overview

Cliff Caldwell Appointed CEO of CIL

October 29, 2019

Tewksbury, MA – October 23, 2019

Cambridge Isotope Laboratories, Inc. (CIL) board of directors appointed Cliff Caldwell as its new chief executive officer (CEO), as Joel Bradley, founder and CEO, stepped down from his position after 38 years. Bradley will remain as a member of the board of directors and will continue to consult for the company.

Caldwell has more than 30 years’ international executive management experience in the manufacture of industrial gases, specialty gases, and chemicals, serving the electronics, pharmaceutical, chemical, research, and high-technology industries. Most recently, he served as a senior vice president with The Linde Group, where he had proven success generating sales, driving organic growth, and increasing revenue in highly dynamic markets.

“Cliff is very familiar with CIL. He has been a customer and already knows many parts of the stable isotope business,” says Bradley. “In his work at Linde, Cliff supervised operations, including production of isotopes and many other UHP gases and specialty electronic products.”

“I’m excited to be leading CIL in its next phases of development,” adds Caldwell. “CIL has the most experienced professionals, exceptionally reliable production, and a strong reputation supporting our customers around the world.”


About Cambridge Isotope Laboratories, Inc.

CIL is the world’s largest manufacturer and global supplier of stable isotopes and stable isotope-labeled compounds used in research, environmental, neonatal, pharmaceutical, medical diagnostic, OLED, and industrial markets. CIL is an operating business owned by Otsuka Pharmaceuticals. The CIL business consists of two facilities in the Boston, MA, area; a large isotope-enrichment production plant in Xenia, OH; CIL Canada in Montreal, Canada; CIL China in Shanghai; ABX in Dresden, Germany; and Eurisotop in Saclay, France.

For more information on CIL, visit


Back to list
CIL News| Cambridge Isotope Laboratories
metabolic substrates, isotope labeling, SILAC Amino Acids, protein standards, SILAC, Metabolic Labeling, NMR Tubes, Nucleic Acid Synthesis, alpha keto acids, Cell-Free Protein Expression, deuterated compounds, biomolecular nor, stable isotope, Hyperpolarization, nuclear medicine isotopes, Stable Isotopes, protein NMR, Protein Reagents, Deuterium labeled compounds, minimal media, Heavy Isotopes, metabolic research, custom synthesis, mass spectrometry, list of stable isotopes, Quantitative Proteomics, Nuclear Medicine, Metabolomics, food testing, Solid State NMR, proteomics, Membrane Proteins, mass spectrometry isotopes, Nucleic Acid, NMR, Protein Expression, material testing, Peptide Synthesis
CIL and its people have been committed to high quality stable isotope labeled products, superior customer service, innovative new products and a breadth of product lines.